Interní Med. 2012; 14(8-9): 303-308

Specific features of treatment of diabetes in the elderly

prof.MUDr.Jaroslav Rybka, DrSc.
Diabetologické centrum IK IPVZ, Krajská nemocnice T. Bati, a. s., Zlín

Diabetes mellitus is the most significant metabolic disease in older age. The course of diabetes and its manifestations, however, are

frequently different in comparison with those in the middle age. The current Czech Diabetes Society (CDS) guidelines are used in the

treatment of diabetes in older age. Emphasis is placed on individualization of treatment that has to be adapted to the health condition

of the elderly patient, particularly in the case of comorbidities. Even in elderly patients with diabetes, achieving glycemic control is

a cornerstone of the therapeutic strategy; however, in elderly diabetics, circumstances need to be taken into account that may result in

a further narrowing of the range within which it is still possible to maintain homeostasis. Prior to initiating therapy, patients are always

evaluated, in addition to comorbidities and diabetic complications, for possible cardiovascular damage, kidney disease, and liver disease.

Based on this, the treatment algorithm, the choice of an antidiabetic agent, and the dosage are adjusted. Also, in elderly patients with

unsatisfactory T2DM control, switching to insulin should in no way be delayed inappropriately. During the treatment, it is necessary

to carefully follow the contraindications of the antidiabetic agents used and to try to avoid the risk of developing hypoglycemia that is

a very serious condition in elderly patients.

Keywords: diabetes mellitus, elderly type 2 diabetics, nonpharmacological measures, oral antidiabetic agents, multimorbidity, specific features of treatment, measures in kidney and liver injury

Published: September 20, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rybka J. Specific features of treatment of diabetes in the elderly. Interní Med. 2012;14(8-9):303-308.
Download citation

References

  1. Škrha J. Inzulinová deficience. In: Perušičová J, a kol. Prediabetes, prehypertenze, dyslipidemie. Praha: Maxdorf 2012, 34-39.
  2. Sinclair AJ. Diabetes in Old Age. In: Textbook of Diabetes, 4th edition. Edited by R. Holt, C. Cockram, A. Flyvbjerg and B. Goldstein. Blackwell Publishing, 2010: 922-939. Go to original source...
  3. Blaum CS. Descriptive epidemiology of diabetes. In: Munsshi MN, Lipsitz LA, eds. Geriatric Diabetes. New York: Informa Healthcare, 2007: 1-10. Go to original source...
  4. Weber P. Diabetes mellitus - specifika a komplikace ve stáří. Interní med. 2008; 10(10): 456-460.
  5. Németh F, Koval Š, Zavázalová H, Baník M. (Prešov, Košice, Plzeň). End of life, Bratislava Medical Journal BLL 2007; 108: 239-245.
  6. Škrha J, Rybka J. 9.3. Diabetes mellitus ve stáří. In: Škrha J et al. Diabetologie. Praha: Galén 2009: 364-371.
  7. Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. International Journal of Clinical Practice 2010; 64: 1705-1711. Go to original source... Go to PubMed...
  8. Doporučené postupy České diabetologické společnosti. Schváleno výborem České diabetologické společnosti ČLS JEP a Českou internistickou společností ČLS JEP dne 20. 1. 2012. DMEV, 15. 1. 2012.
  9. American Diabetes Association. Standards of Medical Care in Diabetes - 2012. Diabetes Care 2012; 35: S11-S63. Go to original source... Go to PubMed...
  10. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glugose tolerance. N Engl J Med 2001; 344: 1343-1350. Go to original source... Go to PubMed...
  11. Kvapil M (ed.) Diabetologie 2012. Praha: Triton 2012. 238 s.
  12. Alberti KGMM, Zimmet P, Shaw J. International Diabezes Federatin: a konsensus on type 2 diabetes preventiv. Diabet. Med., 2007; 24: 451-463. Go to original source... Go to PubMed...
  13. Pozzilli P, Leslie RD, Chan J, DeFronzo R, Monnier L, Raz I, Del Prato S. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician´s personalized approach. Diabetes Metab Res Rev 2010; 26: 239-244. Go to original source... Go to PubMed...
  14. Uličiansky V, Schroner Z, Galajda P, Mokáň M, Némethyová Z. Algoritmus liečby diabetes mellitus 2. typu 2011 v klinickej praxi. Diabetes a obezita, 11, 22, November/2011, 9-29.
  15. Textbook of Diabetes, 4th edition. Edited by Holt R, Cockram C, Flyvbjerg A and Goldstein B. 2010 Blackwell Publishing.
  16. Uličiansky V. Diabetes mellitus v  staršom veku. In: Mokáň M, Martinka E, Galajda P, a kol. Diabetes mellitus a vybrané metabolické ochorenia. Martin, Vydavatelstvo P+M 2008: 861-868.
  17. Šmahelová A. Léčba diabetu u starších diabetiků 2. typu v ambulantní praxi. Interní medicína pro praxi, 2007; 9(9), 378-380.
  18. Pelikánová T. Diabetes ve stáří. In: Pelikánová T, Bartoš V, a kol. Praktická diabetologie. Praha: Maxdorf. 5. Rozšířené vydání, 655-664.
  19. Svačina Š. 4. Klasifikace onemocnění. In: Karen I, Svačina Š, a kol. Diabetes mellitus v primární péči. Praha: Axonite CZ, 2011: 15-20.
  20. Kahn CR, King GL, Moses AC, Weir GC, Jacobson AM, Smith RJ. Joslin's Diabetes Mellitus, 14th edition. Joslin diabetes center. New York: Lippincott Williams & Wilkins 2005. 1224 s.
  21. Haluzík M, Rychlík I, a kol. Léčba diabetu u pacientů s onemocněním ledvin a jater. Praha: Mladá fronta, a.s., 2012: 150 s.
  22. Haluzík M. Léčba diabetiků s chronickým onemocněním ledvin. In: Haluzík M, Rychlík I, a kol. Léčba diabetu u pacientů s onemocněním ledvin a jater. Praha: Mladá fronta, a.s., 2012: 63-99.
  23. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
  24. ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
  25. Duckworth W, Abraira C, Moritz T, et al. for VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139. Go to original source... Go to PubMed...
  26. Suchopár J. Farmakologické vlastnosti a lékové interakce antidiabetik. In: Haluzík M, Rychlík I, a kol. Léčba diabetu u pacientů s onemocněním ledvin a jater. Praha: Mladá fronta, a.s., 2012: 126-137.
  27. Butler PC, Dry S, Elashoff R. GLP-1 based therapy for diabetes: chat you do not know can hurt you. Diabetes Care, 2010; 33: 453-455. Go to original source... Go to PubMed...
  28. Barnet AH, Hulsman H, Jones R, Eynatten M, Patel S, Woerle HJ. Efficacy and Safety of Linagliptin in Elderly Patients ( 70 Years) with Type 2 Diabetes. Poster 1017-P. ADA 72nd Scientific Sessions, 2012. Go to original source...
  29. Rybka J. Inkretiny na prahu roku 2012. Remedia, 1/2012, 50-54.
  30. Adamíková A, Rybka J. Inzulinová analoga a jejich postavení v léčbě. Remedia 4/2011: 339-343.
  31. Fonseca V, Gill J, Zhou R, et al. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes, Obesity and Metabolism 2011; 13: 814-822. Go to original source... Go to PubMed...
  32. Johnston SS, Conner CH, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34(5): 1164-1170. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.